New Eye Drop Approved for Presbyopia

Vizz, the first aceclidine-based solution for presbyopia, was shown in clinical trials to improve near vision in as little as 30 minutes, with effects lasting up to 10 hours. Photo: Lenz Therapeutics. Click image to enlarge. Nearly four years after the launch of Allergan’s pilocarpine-based Vuity comes the approval of Vizz (aceclidine ophthalmic solution 1.44%), the second eye drop for presbyopia, and the first to harness aceclidine—a novel, pupil-selective miotic. The company, Lenz Therapeutics, says the drop works by narrowing the pupil to a sub-2mm pinhole, extending depth of focus for up to 10 hours of near-vision improvement without inducing a myopic shift. The FDA approval of VIZZ was underpinned by three randomized, double-masked, controlled Phase 3 studies—Clarity 1, 2 and 3—with more than 30,000 treatment days of safety data. Clarity 1 and 2 enrolled 466 presbyopic adults dosed once daily for 42 days; both studies met every primary and secondary endpoint, showing a rapid onset of near-vision improvement within 30 minutes and an effect lasting up to 10 hours, according to Lenz. To confirm long-term tolerability, Clarity 3 evaluated 217 participants over six months of once-daily dosing.Across all three trials, the company notes that Vizz was well tolerated with no serious treatment-related adverse events. The most commonly reported reactions were instillation-site irritation (20%), dim vision (16%) and headache (13%). Adverse events occurring in more than 5% of participants included conjunctival hyperemia (8%) and ocular hyperemia (7%). The majority of these reactions were mild, transient and self-resolving, Lenz reports.Samples of the new drop are anticipated to be available in the United States as early as October 2025, with broad commercial launch by mid-Q4 2025. For more information, visit www.vizz.com.